Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for Pancreatic Cancer

The goal of this clinical trial is to evaluate whether a wearable-enabled prehabilitation and rehabilitation pathway can improve recovery and post-operative outcomes in adults undergoing surgery for pancreatic cancer or related pancreatic/periampullary conditions. The main questions it aims to answer are: Does a wearable-enabled prehabilitation and rehabilitation programme reduce post-operative complications within 30 and 90 days after surgery? Is the use of wearable devices and remote monitoring feasible, acceptable, and useful for patients and healthcare professionals during the perioperative pathway? Researchers will compare patients receiving the wearable-enabled pathway with a matched historical control group who received standard care to determine whether the intervention is associated with improved surgical and recovery outcomes. Participants will: Provide informed consent and complete baseline assessments and questionnaires. Take part in the Greater Manchester Prehab4Cancer programme before surgery, including personalised exercise, nutritional support, and wellbeing support. Wear a Corsano CardioWatch device to continuously monitor physiological and activity data. Use home monitoring equipment, including weight scales and blood pressure monitoring devices. Complete questionnaires and participant logs during prehabilitation and recovery. Receive regular support from the research team during participation. Undergo pancreatic surgery and receive standard NHS perioperative care. Continue wearable monitoring and rehabilitation after hospital discharge. Be followed for up to 12 months after surgery using routine clinical data to assess recovery, complications, hospital utilisation, and survival. Optionally participate in a focus group to discuss their experiences of wearable-enabled care.

Sex

All

Minimum age

18 Years

Inclusion Criteria:

* Adult patients aged 18 years or older.
* Able to provide informed consent.
* Able to use the study devices independently or with support from a carer.
* Approved for pancreatic cancer surgery, including patients undergoing surgery for:

Pancreatic cancer Distal cholangiocarcinoma Ampullary carcinoma Duodenal carcinoma Premalignant pancreatic lesions, including Intraductal Papillary Mucinous Neoplasms (IPMNs).

* Clinically stable and considered suitable to participate in the prehabilitation and rehabilitation programme.
* Owns a smartphone or tablet device

Exclusion Criteria:

* Unable or unwilling to provide informed consent.
* Lacks capacity to provide informed consent.
* Unstable angina pectoris.
* Recent myocardial infarction.
* Recent cerebrovascular accident (stroke).
* New cardiac arrhythmia.
* Social, physical, mental health, or substance misuse issues that, in the opinion of the investigator, would jeopardise adherence to study procedures or study contact.
* No infrastructure for remote monitoring (no access to either mobile signal or Wi-Fi).
* Clinically unstable or likely to require hospital admission within the next 72 hours.
* Unable to use the study devices and no carer or support person is available to assist.